- Home >
- Clinicals Trials >
- CAAA617D12302
Cancers urogénitaux
CAAA617D12302
A prospective, multicenter, open-label, randomized international Phase III study evaluating treatment with lutetium (177Lu) vipivotide tetraxetan (AAA617) versus surveillance alone to delay the need for castration or disease recurrence in adult male patients with PSMA-positive oligometastatic prostate cancer.
- Open at Paris since : 26/07/2024
- Open at Saint-Cloud since : 26/07/2024
- Target : Adult
- Phase : Phase III
Trial description
The primary objective of this study is to address the following question: Is the AAA617 treatment effective in delaying the progression of prostate cancer?
Url of the trialMain investigator
